To explore the potential clinical significance of SUFU downregulation by SPOP, we first performed the immunohistochemical staining to evaluate the levels of SPOP and SUFU among 16 different types of cancers, using human tumor tissue microarrays (Fig. 4A, B). The gene discussed is SPOP; the disease is neoplasm.